Profound Medical (PRN.TO) was last seen up 2% in after-hours Nasdaq trade after the company on Tuesday said it sealed a deal with a Saudi Arabian company to distribute Tulsa-Pro and Sonnaleve.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Profound Medical Corp's TULSA-PRO system has the potential to disrupt the surgical treatment of prostate disease. The company is delivering solid growth in recurring and capital revenues. Despite high ...

Doctors perform transurethral ultrasound ablation (TULSA) procedures using the TULSA-PRO system. This treats people with prostate disease, including prostate cancer or an enlarged prostate. New ...

Arun Menawat, CEO of Profound Medical, talks about the company’s innovative TULSA-PRO technology. In a recent interview, Arun Menawat, CEO of Profound Medical, discussed the company’s innovative TULSA ...

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. Profound’s TULSA-PRO qualified sales pipeline also ...

Profound Medical ( (TSE:PRN)) has shared an update. Profound Medical Corp. has regained exclusive distribution rights for its TULSA-PRO® system in Canada from Knight Therapeutics Inc. The TULSA-PRO ...

I am initiating Profound Medical Corp. at a Sell rating with a fair value of $2.9 per share due to financial concerns. TULSA-PRO shows promise for BPH and localized prostate cancer, but long-term ...

Transurethral ultrasound ablation (TULSA) procedures are performed using the TULSA-PRO system when treating people who have prostate disease, including an enlarged prostate and prostate cancer. There ...

TORONTO, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...